FR17C1026I2 - Antidotes d'anticoagulants - Google Patents

Antidotes d'anticoagulants

Info

Publication number: FR17C1026I2
Authority: FR; France
Prior art keywords: antidotes; anticoagulant; anticoagulant antidotes
Prior art date: 2010-01-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR17C1026C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Boehringer Ingelheim International GmbH

Original Assignee

Boehringer Ingelheim International GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-01-20

Filing date

2017-07-10

Publication date

2018-07-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42061991&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR17C1026(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2017-07-10 Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH

2017-09-08 Publication of FR17C1026I1 publication Critical patent/FR17C1026I1/fr

2018-07-20 Application granted granted Critical

2018-07-20 Publication of FR17C1026I2 publication Critical patent/FR17C1026I2/fr

Status Active legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Diabetes (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Cell Biology (AREA)
Pathology (AREA)
Mycology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biotechnology (AREA)
Toxicology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

FR17C1026C 2010-01-20 2017-07-10 Antidotes d'anticoagulants Active FR17C1026I2 (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP10151239		2010-01-20
US38391410P	2010-09-17	2010-09-17
EP11703410.8A EP2525812B1 (en)	2010-01-20	2011-01-20	Anticoagulant antidotes
PCT/EP2011/050749 WO2011089183A2 (en)	2010-01-20	2011-01-20	Anticoagulant antidotes

Publications (2)

Publication Number	Publication Date
FR17C1026I1 FR17C1026I1 (fr)	2017-09-08
FR17C1026I2 true FR17C1026I2 (fr)	2018-07-20

Family

ID=42061991

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR17C1026C Active FR17C1026I2 (fr)	2010-01-20	2017-07-10	Antidotes d'anticoagulants

Country Status (43)

Country	Link
US (3)	US8486398B2 (el)
EP (2)	EP2525812B1 (el)
JP (2)	JP5575923B2 (el)
KR (1)	KR101781787B1 (el)
CN (1)	CN102711813B (el)
AP (1)	AP2012006242A0 (el)
AR (1)	AR079944A1 (el)
AU (1)	AU2011208719C1 (el)
BR (1)	BR112012018021B1 (el)
CA (1)	CA2787566A1 (el)
CO (1)	CO6571889A2 (el)
CY (2)	CY1118875T1 (el)
DK (1)	DK2525812T3 (el)
EA (1)	EA028371B1 (el)
EC (1)	ECSP12012105A (el)
ES (1)	ES2614992T3 (el)
FR (1)	FR17C1026I2 (el)
GE (1)	GEP20156341B (el)
HR (1)	HRP20170613T1 (el)
HU (2)	HUE032263T2 (el)
IL (1)	IL219427B (el)
LT (2)	LT2525812T (el)
LU (1)	LUC00028I2 (el)
MA (1)	MA33936B1 (el)
ME (1)	ME02602B (el)
MX (1)	MX2012008360A (el)
MY (1)	MY162323A (el)
NL (1)	NL300882I2 (el)
NO (2)	NO2017034I1 (el)
NZ (1)	NZ599508A (el)
PE (1)	PE20121516A1 (el)
PH (1)	PH12012501493A1 (el)
PL (1)	PL2525812T3 (el)
PT (1)	PT2525812T (el)
RS (1)	RS55683B1 (el)
SG (1)	SG182552A1 (el)
SI (1)	SI2525812T1 (el)
TN (1)	TN2012000366A1 (el)
TW (1)	TWI513466B (el)
UA (1)	UA110470C2 (el)
UY (1)	UY33196A (el)
WO (1)	WO2011089183A2 (el)
ZA (1)	ZA201202876B (el)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR079944A1 (es) *	2010-01-20	2012-02-29	Boehringer Ingelheim Int	Anticuerpo neutralizante de la actividad de un anticoagulante
PT2663579T (pt)	2011-01-14	2017-07-28	Univ California	Terapêutica de anticorpos contra a proteína r0r-1 e métodos para sua utilização
CN103619883A (zh) *	2011-01-19	2014-03-05	拜耳知识产权有限责任公司	凝血因子抑制剂的结合蛋白
EA201301090A1 (ru) *	2011-03-30	2014-05-30	Бёрингер Ингельхайм Интернациональ Гмбх	Антидоты антикоагулянтов
WO2013082210A1 (en)	2011-11-29	2013-06-06	Perosphere Inc.	Anticoagulant reversal agents
UY35457A (es)	2013-03-14	2014-10-31	Bayer Healthcare Llc	ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA ß
EP3060583A1 (en) *	2013-10-25	2016-08-31	Boehringer Ingelheim International GmbH	Anticoagulant antidotes
TW201623331A (zh) *	2014-03-12	2016-07-01	普羅帝納生物科學公司	抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
CN105223348A (zh) *	2014-05-26	2016-01-06	北京九强生物技术股份有限公司	人抗凝血酶iii的胶乳增强免疫比浊法检测试剂盒
EP2980218A1 (en) *	2014-07-30	2016-02-03	Rheinische Friedrich-Wilhelms-Universität Bonn	Aptamer thrombin complex for use as an antidote to direct acting thrombin inhibitors
WO2016019145A1 (en) *	2014-07-31	2016-02-04	Haemonetics Corporation	Detection and classification of an anticoagulant using a clotting assay
US10300154B2 (en)	2014-09-17	2019-05-28	David R Elmaleh	Anticoagulant derivatives for cardiovascular imaging
JP6581197B2 (ja)	2014-12-31	2019-09-25	深▲セン▼市薬欣生物科技有限公司ＳｈｅｎｚｈｅｎＰｈａｒｍａｃｉｎＣｏ．，Ｌｔｄ．	医薬組成物及びその製造方法
US10449195B2 (en)	2016-03-29	2019-10-22	Shenzhen Pharmacin Co., Ltd.	Pharmaceutical formulation of palbociclib and a preparation method thereof
US11879014B2 (en)	2017-03-17	2024-01-23	Tusk Therapeutics Ltd.	Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
AU2018388079B2 (en) *	2017-12-24	2024-11-14	Noile-Immune Biotech, Inc.	Immunocompetent cell that expresses a cell surface molecule specifically recognizing human mesothelin, IL-7 and CCL19
WO2019175222A1 (en)	2018-03-13	2019-09-19	Tusk Therapeutics Ltd	Anti-cd25 for tumour specific cell depletion
CA3099974A1 (en)	2018-05-11	2019-11-14	Halcyon Therapeutics, Inc.	Binding proteins and chimeric antigen receptor t cells targeting gasp-1 granules and uses thereof
JP7503561B2 (ja)	2018-10-29	2024-06-20	ファーハイユーエスインコーポレイテッド	新規ジペプチド化合物及びその使用方法
WO2020180489A1 (en)	2019-03-06	2020-09-10	University Of Rochester	Anticoagulant compositions and uses thereof
CN114306245A (zh)	2020-09-29	2022-04-12	深圳市药欣生物科技有限公司	无定形固体分散体的药物组合物及其制备方法
TW202321311A (zh) *	2021-08-02	2023-06-01	日商諾伊爾免疫生物科技股份有限公司	與scFv等之連接子結合的抗體
US11446286B1 (en) *	2022-02-28	2022-09-20	King Faisal University	Treatment of fungal infections using dabigatran etexilate
NL2036011B1 (en)	2023-10-12	2025-04-30	Synapse Res Institute	Molecules for reversing anti-coagulant activity of direct oral anticoagulants
WO2025149667A1 (en)	2024-01-12	2025-07-17	Pheon Therapeutics Ltd	Antibody drug conjugates and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6087380A (en)	1949-11-24	2000-07-11	Boehringer Ingelheim Pharma Kg	Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
WO1988001649A1 (en)	1986-09-02	1988-03-10	Genex Corporation	Single polypeptide chain binding molecules
FI903489A0 (fi)	1988-11-11	1990-07-10	Medical Res Council	Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
US5910573A (en) *	1992-01-23	1999-06-08	Merck Patent Gesellschaft Mit Beschrankter Haftung	Monomeric and dimeric antibody-fragment fusion proteins
DE4203965A1 (de)	1992-02-11	1993-08-12	Max Planck Gesellschaft	Antidot fuer hirudin und synthetische thrombininhibitoren
ATE427968T1 (de)	1992-08-21	2009-04-15	Univ Bruxelles	Immunoglobuline ohne leichtkette
ATE199392T1 (de)	1992-12-04	2001-03-15	Medical Res Council	Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
DE69420137T2 (de)	1993-06-03	1999-12-23	Therapeutic Antibodies, Inc.	Herstellung von antikörperfragmenten
AT404357B (de)	1995-06-13	1998-11-25	Immuno Ag	Prothrombin-derivate
DE19605126A1 (de)	1996-02-12	1997-08-14	Basf Ag	Thrombinmuteine als Antidot für Thrombininhibitoren
US6200955B1 (en)	1996-06-11	2001-03-13	Commonwealth Biotechnologies, Inc.	Heparin binding peptides
GB9625640D0 (en)	1996-12-10	1997-01-29	Celltech Therapeutics Ltd	Biological products
PE121699A1 (es)	1997-02-18	1999-12-08	Boehringer Ingelheim Pharma	Heterociclos biciclicos disustituidos como inhibidores de la trombina
WO1998048837A1 (en)	1997-04-30	1998-11-05	Enzon, Inc.	Polyalkylene oxide-modified single chain polypeptides
DE19729544A1 (de) *	1997-07-10	1999-01-14	Basf Ag	Ancrod spezifische monoklonale Antikörper, Antikörperfragmente, deren Mischung oder Derivate und deren Verwendung
US6440417B1 (en)	1998-11-06	2002-08-27	Conjuchem, Inc.	Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments
US6624141B1 (en)	1999-03-17	2003-09-23	The Regents Of The University Of Michigan	Protamine fragment compositions and methods of use
EP1803730A1 (en)	2000-04-12	2007-07-04	Human Genome Sciences, Inc.	Albumin fusion proteins
CN1911965B (zh)	2001-01-17	2013-05-29	新兴产品开发西雅图有限公司	结合域-免疫球蛋白融合蛋白
US20040097547A1 (en)	2001-04-16	2004-05-20	Taveras Arthur G.	3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US20070031438A1 (en) *	2001-12-10	2007-02-08	Junghans Richard P	Antibodies as chimeric effector cell receptors against tumor antigens
US20050214857A1 (en)	2001-12-11	2005-09-29	Algonomics N.V.	Method for displaying loops from immunoglobulin domains in different contexts
DK1517921T3 (da)	2002-06-28	2006-10-09	Domantis Ltd	Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
EP3299393A1 (en)	2002-11-08	2018-03-28	Ablynx N.V.	Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
AU2004220325B2 (en)	2003-06-30	2011-05-12	Domantis Limited	Polypeptides
DK2915564T3 (da) *	2007-09-28	2021-02-08	Alexion Pharma Inc	Antidoter mod faktor XA-inhibitorer og fremgangsmåder til anvendelse deraf
AR070141A1 (es) *	2008-01-23	2010-03-17	Glenmark Pharmaceuticals Sa	Anticuerpos humanizados especificos para el factor von willebrand
BR112012004169A2 (pt)	2009-08-24	2016-03-29	Boehringer Ingelheim Int	intervenções de emergência com carvão vegetal ativado em superdosagem de etexilato de dabigatran
AR079944A1 (es)	2010-01-20	2012-02-29	Boehringer Ingelheim Int	Anticuerpo neutralizante de la actividad de un anticoagulante

2011
- 2011-01-19 AR ARP110100179A patent/AR079944A1/es active IP Right Grant
- 2011-01-19 TW TW100102006A patent/TWI513466B/zh active
- 2011-01-20 CN CN201180006616.4A patent/CN102711813B/zh active Active
- 2011-01-20 UY UY0001033196A patent/UY33196A/es active IP Right Grant
- 2011-01-20 SG SG2012052445A patent/SG182552A1/en unknown
- 2011-01-20 ES ES11703410.8T patent/ES2614992T3/es active Active
- 2011-01-20 SI SI201131156A patent/SI2525812T1/sl unknown
- 2011-01-20 KR KR1020127019086A patent/KR101781787B1/ko active Active
- 2011-01-20 HR HRP20170613TT patent/HRP20170613T1/hr unknown
- 2011-01-20 WO PCT/EP2011/050749 patent/WO2011089183A2/en not_active Ceased
- 2011-01-20 MX MX2012008360A patent/MX2012008360A/es active IP Right Grant
- 2011-01-20 EP EP11703410.8A patent/EP2525812B1/en active Active
- 2011-01-20 CA CA2787566A patent/CA2787566A1/en not_active Abandoned
- 2011-01-20 MY MYPI2012002840A patent/MY162323A/en unknown
- 2011-01-20 PE PE2012000997A patent/PE20121516A1/es active IP Right Grant
- 2011-01-20 ME MEP-2017-29A patent/ME02602B/me unknown
- 2011-01-20 DK DK11703410.8T patent/DK2525812T3/en active
- 2011-01-20 PH PH1/2012/501493A patent/PH12012501493A1/en unknown
- 2011-01-20 PL PL11703410T patent/PL2525812T3/pl unknown
- 2011-01-20 PT PT117034108T patent/PT2525812T/pt unknown
- 2011-01-20 HU HUE11703410A patent/HUE032263T2/en unknown
- 2011-01-20 JP JP2012549355A patent/JP5575923B2/ja active Active
- 2011-01-20 BR BR112012018021-5A patent/BR112012018021B1/pt active IP Right Grant
- 2011-01-20 GE GEAP201112836A patent/GEP20156341B/en unknown
- 2011-01-20 UA UAA201209779A patent/UA110470C2/ru unknown
- 2011-01-20 MA MA35080A patent/MA33936B1/fr unknown
- 2011-01-20 EA EA201201016A patent/EA028371B1/ru active Protection Beyond IP Right Term
- 2011-01-20 EP EP16205771.5A patent/EP3195876A1/en not_active Withdrawn
- 2011-01-20 AU AU2011208719A patent/AU2011208719C1/en active Active
- 2011-01-20 RS RS20170195A patent/RS55683B1/sr unknown
- 2011-01-20 AP AP2012006242A patent/AP2012006242A0/xx unknown
- 2011-01-20 US US13/010,403 patent/US8486398B2/en active Active
- 2011-01-20 NZ NZ599508A patent/NZ599508A/en unknown
- 2011-01-20 LT LTEP11703410.8T patent/LT2525812T/lt unknown
2012
- 2012-04-19 ZA ZA2012/02876A patent/ZA201202876B/en unknown
- 2012-04-25 IL IL219427A patent/IL219427B/en active IP Right Grant
- 2012-07-18 TN TNP2012000366A patent/TN2012000366A1/en unknown
- 2012-07-23 CO CO12123109A patent/CO6571889A2/es active IP Right Grant
- 2012-08-14 EC ECSP12012105 patent/ECSP12012105A/es unknown
2013
- 2013-06-13 US US13/916,994 patent/US9034822B2/en active Active
2014
- 2014-07-02 JP JP2014136811A patent/JP2014210794A/ja active Pending
2015
- 2015-04-13 US US14/684,576 patent/US20150210778A1/en not_active Abandoned
2017
- 2017-03-22 CY CY20171100361T patent/CY1118875T1/el unknown
- 2017-07-06 NL NL300882C patent/NL300882I2/nl unknown
- 2017-07-10 FR FR17C1026C patent/FR17C1026I2/fr active Active
- 2017-07-10 LT LTPA2017021C patent/LTC2525812I2/lt unknown
- 2017-07-10 CY CY2017025C patent/CY2017025I1/el unknown
- 2017-07-11 NO NO2017034C patent/NO2017034I1/no unknown
- 2017-07-12 LU LU00028C patent/LUC00028I2/fr unknown
- 2017-07-13 HU HUS1700030C patent/HUS1700030I1/hu unknown
2022
- 2022-08-12 NO NO2022036C patent/NO2022036I1/no unknown

Also Published As

Publication number	Publication date
EA201201016A1 (ru)	2013-02-28
EP3195876A1 (en)	2017-07-26
AU2011208719A1 (en)	2012-05-17
CY1118875T1 (el)	2018-01-10
HRP20170613T1 (hr)	2017-06-30
CO6571889A2 (es)	2012-11-30
WO2011089183A3 (en)	2011-11-17
PE20121516A1 (es)	2012-11-24
CN102711813B (zh)	2015-03-04
US20150210778A1 (en)	2015-07-30
SG182552A1 (en)	2012-08-30
ME02602B (me)	2017-06-20
DK2525812T3 (en)	2017-02-27
CY2017025I2 (el)	2017-11-14
LUC00028I1 (el)	2017-07-14
JP2013517317A (ja)	2013-05-16
EP2525812A2 (en)	2012-11-28
JP2014210794A (ja)	2014-11-13
ZA201202876B (en)	2012-12-27
BR112012018021B1 (pt)	2020-12-08
US8486398B2 (en)	2013-07-16
NZ599508A (en)	2014-05-30
TWI513466B (zh)	2015-12-21
EA028371B1 (ru)	2017-11-30
CY2017025I1 (el)	2017-11-14
LTPA2017021I1 (lt)	2017-07-25
TN2012000366A1 (en)	2014-01-30
NO2022036I1 (no)	2022-08-12
BR112012018021A2 (pt)	2017-06-20
AR079944A1 (es)	2012-02-29
CA2787566A1 (en)	2011-07-28
RS55683B1 (sr)	2017-07-31
MX2012008360A (es)	2012-08-08
UY33196A (es)	2011-08-31
KR101781787B1 (ko)	2017-09-26
IL219427A0 (en)	2012-06-28
IL219427B (en)	2018-05-31
ES2614992T3 (es)	2017-06-02
UA110470C2 (ru)	2016-01-12
HK1173957A1 (en)	2013-05-31
HUS1700030I1 (hu)	2017-08-28
WO2011089183A2 (en)	2011-07-28
MA33936B1 (fr)	2013-01-02
CN102711813A (zh)	2012-10-03
PL2525812T3 (pl)	2017-07-31
ECSP12012105A (es)	2012-10-30
EP2525812B1 (en)	2017-01-18
US20120027780A1 (en)	2012-02-02
US20130289248A1 (en)	2013-10-31
FR17C1026I1 (fr)	2017-09-08
PH12012501493A1 (en)	2012-10-22
NL300882I2 (nl)	2017-07-20
NO2017034I1 (no)	2017-07-11
TW201136606A (en)	2011-11-01
AP2012006242A0 (en)	2012-04-30
HUE032263T2 (en)	2017-09-28
JP5575923B2 (ja)	2014-08-20
MY162323A (en)	2017-05-31
LT2525812T (lt)	2017-02-27
SI2525812T1 (sl)	2017-05-31
PT2525812T (pt)	2017-04-26
KR20120128126A (ko)	2012-11-26
LUC00028I2 (el)	2017-09-25
LTC2525812I2 (lt)	2019-05-10
AU2011208719C1 (en)	2017-07-13
US9034822B2 (en)	2015-05-19
GEP20156341B (en)	2015-08-10

Publication	Publication Date	Title
FR17C1026I2 (fr)	2018-07-20	Antidotes d'anticoagulants
IL257693B (en)	2019-12-31	Fungicidal compositions
EP2849648A4 (en)	2016-01-13	ANALYZER WITH FISH EYE LENS
BR112013015783A2 (pt)	2018-05-29	autoinjetor.
EP2864483A4 (en)	2015-06-10	ARRANGEMENT FOR TRANSCRIPTING AN ACTIVE-ORIENTED EFFECTOR ARRANGEMENT
BR112013008401A2 (pt)	2016-06-21	autoinjetor
EP2535065A4 (en)	2014-07-23	DIALYSIS MACHINE
EP2901300A4 (en)	2016-05-18	PROVIDING EXTERNAL IDENTIFICATORS
CO6771448A2 (es)	2013-10-15	Antídotos anticoagulantes
DK2590565T3 (da)	2014-08-25	Blodprøvetagning
FR2964299B3 (fr)	2012-10-12	Taille-haie
EP2786712A4 (en)	2015-07-01	atherectomy
EP2628733A4 (en)	2014-02-26	ACYLBENZEN DERIVATIVE
BR112013010223A2 (pt)	2017-05-23	"piranosidade temperatura- estável"
FR2970577B1 (fr)	2014-02-07	Plateforme d'execution modulaire amelioree.
FR2987772B1 (fr)	2015-04-17	Chargeur d'etuis robotise
FR2959437B1 (fr)	2012-06-08	Micro-actionneur et micro-pince
IT1403336B1 (it)	2013-10-17	Cassettiera.
FR2966743B3 (fr)	2012-11-30	Agres d'equilibre.
ES1076557Y (es)	2012-06-18	"juguete saltador"
FR2995130B3 (fr)	2015-03-20	Commutateur d'urgence
ITAL20100015U1 (it)	2011-12-12	"il salvagiornale"
IT1404107B1 (it)	2013-11-08	Portamenu'.
ES1075739Y (es)	2012-02-23	"foco empotrable"
UA22288S (uk)	2011-10-10	Жатка валкова